Treg cell therapy for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with type 1 diabetes
- You are between 8 and 65 years old
- You have at least one diabetes-related antibody in your blood, or your fasting C-peptide level is 300 pmol/L or below
- You are willing to sign a consent form and follow the study rules
- You must not have uncontrolled diabetic ketoacidosis, known cancer, severe allergies, or certain other serious health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational gene therapy that may help people with type 1 diabetes produce some insulin on their own, potentially reducing the amount of insulin they need. It is an early-stage study, so participants will be closely monitored for safety and any changes in their diabetes control.
This study tests a new gene therapy (VV-14300) that aims to help people with type 1 diabetes make insulin again. It might improve blood sugar control and reduce the need for insulin.
This early-stage trial is testing a new approach to slow or stop the loss of insulin-making cells in people who were recently diagnosed with type 1 diabetes. It uses a medicine called teplizumab to adjust the immune system, and the goal is to help you keep making your own insulin for as long as possible.
This trial tests a new treatment made from stem cells that may help people with diabetes who have dangerous low blood sugar episodes. It aims to see if these cells can replace some of the pancreas function and prevent severe hypoglycemia.
This trial tests a new one-time treatment called CARC-101C for people recently diagnosed with type 1 diabetes. It aims to see if this treatment can help preserve the body's ability to make insulin and improve blood sugar control.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.